• About
  • Policies
  • What is open access
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • University Library
      • Bilkent Theses
      • Theses - Graduate Program in Neuroscience
      • Graduate Program in Neuroscience - Ph.D. / Sc.D.
      • View Item
      •   BUIR Home
      • University Library
      • Bilkent Theses
      • Theses - Graduate Program in Neuroscience
      • Graduate Program in Neuroscience - Ph.D. / Sc.D.
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Identification of preclinical implications for novel indole-benzimidazoles and phenothiazines using in vitro cancer cell line and in vivo zebrafish models

      Thumbnail
      Embargo Lift Date: 2021-03-29
      View / Download
      12.5 Mb
      Author(s)
      Yaman, Murat
      Advisor
      Karakayalı, Özlen Konu
      Date
      2020-09
      Publisher
      Bilkent University
      Language
      English
      Type
      Thesis
      Item Usage Stats
      235
      views
      126
      downloads
      Abstract
      Breast cancer (BC) and hepatocellular carcinoma (HCC) are two major health problems with significant mortality rates. Although drug therapies are available, therapeutic success remains limited. Because of low bioavailability, high toxicity and recurring drug resistance, novel therapeutic options are essential. In the present thesis, a multitude of in vitro, in silico and in vivo approaches were executed to test anti-cancer effects and preclinical potentials of novel indole-benzimidazoles and phenothiazines in BC and HCC, respectively. In the first component of the thesis, I evaluated BC cell line toxicity and estrogen receptor (ER) relationship of novel indole-benzimidazole derivatives using in vitro cancer lines, in vivo zebrafish embryos/larvae, and in silico comparative transcriptomics analyses. In the second part, antipsychotic compounds phenothiazines (PTZ) were repurposed for HCC therapy. Therefore, generic PTZ derivatives alone or in combination with sorafenib (SFB) were tested using in vitro cancer lines followed by zebrafish developmental assays and embryonic stage xenografts. In addition, RNAseq analyses were performed on trifluoperazine (TFP), SFB, and TFP+SFB combination treated Hep3B cells to understand synergistic/antagonistic effects of the drugs at gene expression level. Lastly, anti-HCC potential of novel PTZ derivatives were explored by in vitro and in vivo screenings. Moreover, effects of the novel and generic derivatives on neural pathways were evaluated by cholinesterase assays and motor response measurements. The findings of the dissertation present potential leads for conducting further preclinical studies tailored towards novel BC and HCC therapies.
      Keywords
      Breast cancer
      Hepatocellular carcinoma
      Indole-benzimidazoles
      Phenothiazines
      Sorafenib synergism
      Drug repurposing
      Preclinical drug discovery
      In vitro / in vivo toxicity profiling
      Behavioral assays
      Acetylcholinesterase
      Comparative transcriptomics
      Permalink
      http://hdl.handle.net/11693/54208
      Collections
      • Graduate Program in Neuroscience - Ph.D. / Sc.D. 13
      Show full item record

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCoursesThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCourses

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 2976
      © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy